WHO ICTRP trial
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological…
CTIS2025-521127-73-00 · EU Clinical Trials Information System · Recruiting
Key facts
| Trial ID | CTIS2025-521127-73-00 |
|---|---|
| Public title | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis |
| Scientific title | A Phase 3, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Evaluate The Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects Of Subcutaneous Ublituximab Versus Intravenous Ublituximab In Patients With Multiple Sclerosis - TG1101-RMS-SC301 |
| Primary sponsor | Tg Therapeutics Inc. |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): No Therapeutic confirmatory - (Phase III): Yes Therapeutic use - (Phase IV): No |
| Countries | Bosnia and Herzegovina;North Macedonia;Ukraine;Serbia;Georgia;Bulgaria;Croatia;Czechia;Hungary |
| Conditions | Relapsing forms of Multiple Sclerosis MedDRA version: 27.0Level: PTClassification code: 10080700Term: Relapsing multiple sclerosis Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] |
| Interventions | Product Name: Ublituximab, Product Code:PRD12001815, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: ublituximab, Product Code:PRD5447378, Pharmaceutical Form: CONCENTRATE FOR SOLUTION FOR… |
| Registration date | Apr 25, 2025 |
| Target size | 360 |
| Secondary IDs | U1111-1320-5618 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: